

MONTHLY MEDICATION SAFETY UPDATE

Information for health professionals in NSW public health organisations

This is a summary of medication safety and supply related issues affecting NSW public health facilities in **October 2023**. Updates regarding current medication-specific safety and supply related issues are available on the [CEC website](#).

Medication safety issues under investigation

- Discontinuation of Neupogen (filgrastim) – **Medication Safety Communication** being prepared.
- Fluid therapy and medicine dosing in adult patients who have low body weight – **Safety Information** being finalised in consultation with eHealth Safety and Quality Advisory Group.
- Discontinuation of multiple opioid formulations (Ms Mono®, Sevredol®, OxyNorm® capsules) by Mundipharma Pty Limited.
- Actively monitoring disruption to the supply of olanzapine depot injections.

Relevant clinician information to note

- TGA updates:
 - Baclofen off-label prescribing – [safety update](#)
 - Ethical Nutrients Mega Magnesium Raspberry Powder – [product recall](#)
 - [Product Information safety updates – October 2023](#)
- The CEC has released updated [Direct Oral Anticoagulation \(DOAC\) Guidelines](#) (formerly named NOAC Guidelines) to reflect current practice and best evidence, as well as include prescribing and administration guidance to support the safe use of andexanet alfa.
- The CEC's [Life Saving Drugs Register solution](#) is live – more information available [here](#).

Current projects with eHealthNSW

- Continued collaboration on the VTE Prevention eMR project, working towards a pilot beginning in November 2023.
- Continued collaboration on the NSW Medicines Formulary online platform. The Admin User Interface functionality has now been released and enables agile management of formulary listing data sets. Reporting functionality is scheduled for release in December 2023 and will enable end users to download an extract of the NSW Medicines Formulary.

Medication Safety and Supply Summary

33	SAFETY/SUPPLY ISSUES REQUIRING INVESTIGATION BY THE MEDICATION SAFETY TEAM
5	WERE REPORTED TO THE FRONTLINE DUE TO SAFETY RISK REQUIRING LOCAL MITIGATION
1	RESULTED IN FORMAL SAFETY COMMUNICATION
0	PREVIOUS ISSUES RESOLVED ON CEC ONLINE PORTAL

Safety Alerts/Notices/Information released

SN:028/23 [Discontinuation of all strengths of immediate-release morphine hydrochloride trihydrate \(Ordine®\) oral solution in Australia](#) – 17 October 2023

Medication Safety Communications released

Nil.

Medications reported on online portal this month

[Benzathine benzylpenicillin, mesna tablets, morphine hydrochloride \(Ordine\) oral solution, olanzapine depot injections, paracetamol solution for injection](#)

Contact us

If you need support or assistance with medication safety matters in your facility, please email us

CEC-MedicationSafety@health.nsw.gov.au.